Renal Cell Carcinoma | Disease Landscape & Forecast | G7 | 2021
The renal cell carcinoma market is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical), Keytruda (Merck & Co.) plus Inlyta (Pfizer), and Bavencio (Pfizer / Merck KGaA) plus Inlyta, are revolutionizing the treatment of advanced disease. The recent approval and uptake of the Opdivo plus Cabometyx (Exelixis / Ipsen) combination will also drive fierce competition in this setting. Multiple immune checkpoint inhibitors are also anticipated to enter the early-stage setting over the forecast period. Additionally, the anticipated entry of other agents such as bempegaldesleukin (Nektar Therapeutics) and belzutifan (Merck & Co.) will further diversify treatment options and create a highly competitive and dynamic market.
Questions Answered
- What is the size of the advanced or metastatic drug-treatable renal cell carcinoma population, and how will drug-treatment rates change over time?
- What is the expected market impact of recent drug approvals and label expansions of novel combinations incorporating Opdivo, Cabometyx, and Keytruda for renal cell carcinoma?
- Which are the most promising emerging therapies in the late-phase pipeline, and how will they shape the future of the renal cell carcinoma?
- What are the drivers and constraints in the renal cell carcinoma market, and how will the market evolve over the forecast period?
Product Description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
